<DOC>
	<DOCNO>NCT02560779</DOCNO>
	<brief_summary>The purpose phase 1b portion evaluate safety tolerability determine recommend phase 2 dose TRC105 add standard dose sorafenib patient hepatocellular carcinoma . Up 18 patient treat . The purpose phase 2 portion estimate ORR patient hepatocellular carcinoma RECIST 1.1 . Up 21 patient treat phase 2 .</brief_summary>
	<brief_title>Trial TRC105 Sorafenib Patients With HCC</brief_title>
	<detailed_description>Sorafenib oral multikinase inhibitor target several receptor tyrosine kinase , include VEGF receptor ( VEGFR ) , implicate pathologic angiogenesis , tumor growth , cancer progression . Sorafenib approve treatment unresectable hepatocellular carcinoma ( HCC ) . TRC105 antibody endoglin , important angiogenic target proliferate endothelial cell distinct VEGFR . TRC105 inhibit angiogenesis , tumor growth metastases complement activity bevacizumab multi-kinase inhibitor target VEGFR preclinical model . Together , use TRC105 sorafenib may result effective angiogenesis inhibition improve clinical efficacy see sorafenib alone .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>1 . Patients must confirm hepatocellular carcinoma ( HCC ) histopathology image criterion accord AASLD guideline . 2 . Patients must disease amenable potentially curative resection ablative technique recur follow ablative technique . In addition , disease must amenable transhepatic arterial chemoembolization ( TACE ) must progress TACE . Patients must candidate liver transplantation . 3 . If liver cirrhosis present , patient must ChildPugh A B ( 7 point ) classification . 4 . No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , adequately treated Stage I II cancer patient currently complete remission per investigator ' clinical judgment . 5 . Measurable disease RECIST 1.1 ( Phase 2 ) 6 . Age 18 year old 7 . ECOG performance status ≤ 1 8 . Resolution acute adverse event result prior cancer therapy NCI CTCAE grade ≤ 1 baseline 9 . Adequate organ function 10 . Willingness ability consent participate study 11 . Willingness ability comply schedule visit , treatment plan , laboratory test , study procedure 12 . Men sterile OR agree use least two form reliable highly effective method birth control donate sperm least 180 day follow last dose TRC105 sorafenib . 13 . Woman nonchild bear potential due surgical sterilization confirm medical history menopause , OR woman child bear potential test negative pregnancy time enrollment base serum pregnancy test agree use least 2 form reliable highly effective method birth control study least 180 day stop TRC105 sorafenib . 1 . Prior anticancer systemic therapy 2 . Current treatment another therapeutic clinical trial 3 . Prior radiation therapy within 28 day start study treatment 4 . No major surgical procedure significant traumatic injury within 6 week prior study registration , must fully recovered procedure . 5 . Proteinuria 6 . Uncontrolled chronic hypertension define systolic &gt; 150 diastolic &gt; 90 despite optimal therapy . 7 . History brain involvement cancer , spinal cord compression , carcinomatous meningitis , new evidence brain leptomeningeal disease . 8 . Angina , MI , symptomatic congestive heart failure , cerebrovascular accident , transient ischemic attack , arterial embolism , pulmonary embolism , PTCA CABG within past 6 month . 9 . Active bleed pathologic condition carry high risk bleeding . No bleed diathesis . 10 . Thrombolytic use within 10 day prior first day study therapy 11 . History hemorrhage hemoptysis ( &gt; ½ teaspoon bright red blood ) within 3 month start study treatment 12 . Need anticoagulation 13 . History liver transplant 14 . History bleed esophageal varix previous 6 month , adequately manage band sclerotherapy . 15 . History peptic ulcer disease within 3 month treatment . 16 . Known human immunodeficiency virus ( HIV ) acquire immunodeficiency syndrome ( AIDS ) relate illness 17 . Patients may receive strong CYP3A4 inducer within 12 day prior registration strong CYP3A4 inhibitor within 7 day prior registration 18 . Patients know hypersensitivity Chinese hamster ovary product recombinant human , chimeric , humanized antibody . 19 . Other severe acute chronic medical psychiatric condition laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>TRC105</keyword>
	<keyword>CD105</keyword>
	<keyword>Endoglin</keyword>
	<keyword>Angiogenesis inhibitor</keyword>
	<keyword>HCC</keyword>
	<keyword>TKI</keyword>
	<keyword>Tyrosine Kinase Inhibitor</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>Nexavar</keyword>
</DOC>